BARD1 ^Companies

BARD1 is a protein released in an aberrant form by cancer cells and that is used for the diagnostic of lung cancer. BARD1AG is developing a non-invasive test based on BARD1 antibodies and RNA splice-variants. The tests are composed of an ELISA-based test (“screening”) to detect anti-BARD1 antibodies in serum, followed by an analysis of BARD1 isoforms-specific RNA in circulating tumour cells (CTCs) (“final diagnosis”). Both tests are expected to be “CE-marked” by fall 2013. The tests will be asked for by your doctor, who will first puncture a small drop of blood and send it to BARD1AG for analysis. If positive, you will be asked for a second, and somewhat larger blood sampling for definitive diagnosis.